Hari B Keshava1, Andrew Tang1, Hafiz Umair Siddiqui1, Siva Raja1, Daniel P Raymond1, Alejandro Bribriesco1, James Stevenson1, Sudish C Murthy1, Usman Ahmad2. 1. Department of Thoracic and Cardiovascular Surgery, Taussig Cancer Center, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue / Mail Stop J4-1, Cleveland, OH, 44195, USA. 2. Department of Thoracic and Cardiovascular Surgery, Taussig Cancer Center, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue / Mail Stop J4-1, Cleveland, OH, 44195, USA. ahmadu@ccf.org.
Abstract
BACKGROUND: Projections based on regulations curtailing asbestos use in the USA suggest that peak incidence of pleural mesothelioma would occur between 2000 and 2005 and then decline. We analyzed the National Cancer Database (NCDB) to assess current trends in disease incidence, patient demographics, cancer treatment, and survival. METHODS: The NCDB was queried to identify patients diagnosed with pleural mesothelioma from 2004 through 2014. Clinical and pathologic characteristics, treatments, and survival were analyzed. Risk factors for death were identified by multivariable Cox regression. RESULTS: A total of 20,988 patients with pleural mesothelioma were reported to the NCDB. The number of cases per year increased from 1783 to 1961, accounting for roughly 0.3% of all reported cancers each year. The proportion of elderly patients increased from 75 to 80%, but distribution by sex remained constant (20% female). The proportion of patients undergoing treatment increased from 34 to 54%. One-year survival increased from 37 to 47% and 3-year survival from 9 to 15% (p < 0.001). Factors associated with improved survival included younger age, female sex, epithelioid histology, treatment in an academic center, health insurance, higher income, and multimodality therapy. CONCLUSIONS: The annual incidence of mesothelioma has not declined this century and remains stable. Reporting of histologic and clinical staging has improved. National trends suggest that survival is slowly increasing despite an aging cohort. Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival.
BACKGROUND: Projections based on regulations curtailing asbestos use in the USA suggest that peak incidence of pleural mesothelioma would occur between 2000 and 2005 and then decline. We analyzed the National Cancer Database (NCDB) to assess current trends in disease incidence, patient demographics, cancer treatment, and survival. METHODS: The NCDB was queried to identify patients diagnosed with pleural mesothelioma from 2004 through 2014. Clinical and pathologic characteristics, treatments, and survival were analyzed. Risk factors for death were identified by multivariable Cox regression. RESULTS: A total of 20,988 patients with pleural mesothelioma were reported to the NCDB. The number of cases per year increased from 1783 to 1961, accounting for roughly 0.3% of all reported cancers each year. The proportion of elderly patients increased from 75 to 80%, but distribution by sex remained constant (20% female). The proportion of patients undergoing treatment increased from 34 to 54%. One-year survival increased from 37 to 47% and 3-year survival from 9 to 15% (p < 0.001). Factors associated with improved survival included younger age, female sex, epithelioid histology, treatment in an academic center, health insurance, higher income, and multimodality therapy. CONCLUSIONS: The annual incidence of mesothelioma has not declined this century and remains stable. Reporting of histologic and clinical staging has improved. National trends suggest that survival is slowly increasing despite an aging cohort. Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival.
Authors: H R Menck; M P Cunningham; J M Jessup; H J Eyre; D P Winchester; C E Scott-Conner; G P Murphy Journal: Cancer Date: 1997-12-15 Impact factor: 6.860
Authors: Aliya Noor Husain; Thomas V Colby; Nelson G Ordóñez; Timothy Craig Allen; Richard Luther Attanoos; Mary Beth Beasley; Kelly Jo Butnor; Lucian R Chirieac; Andrew M Churg; Sanja Dacic; Françoise Galateau-Sallé; Allen Gibbs; Allen M Gown; Thomas Krausz; Leslie Anne Litzky; Alberto Marchevsky; Andrew G Nicholson; Victor Louis Roggli; Anupama K Sharma; William D Travis; Ann E Walts; Mark R Wick Journal: Arch Pathol Lab Med Date: 2017-07-07 Impact factor: 5.534
Authors: Nola J Olsen; Peter J Franklin; Alison Reid; Nicholas H de Klerk; Timothy J Threlfall; Keith Shilkin; Bill Musk Journal: Med J Aust Date: 2011-09-05 Impact factor: 7.738
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209